BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Celltech Pharmaceuticals Ltd submitted on 11 March 2004 an application for Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  through  the  centralised  procedure  for 
Xyrem which was designated as an orphan medicinal product EU/3/02/31 on 03 February 2003. On 30 
December 2004 the EMEA was notified that following acquisition of Celltech by UCB Pharma, the 
ownership rights for Xyrem application were transferred to UCB Pharma..  
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Prof Cristina Sampaio 
Co-Rapporteur:  Dr Jens Ersbøll 
Licensing status: 
Xyrem has been given a Marketing Authorisation in The United States of America on 17 July 2002.  
Applications were filed in the following countries: Canada and Switzerland. 
Steps taken for the assessment of the product 
2. 
•  The procedure started on 29 March 2004. 
• 
The  Rapporteur's  and  Co-Rapporteur's  first  Assessment  Report  were  circulated  to  all  CHMP 
members on 15 June 2004 . 
• 
• 
• 
• 
• 
• 
• 
• 
During  the  meeting  on  27-29  July  2004,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  29 July 2004. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  11 
March 2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 16 May 2005. 
An expert panel meeting was convened on 23 May 2005. 
During the CHMP meeting on 23-26 May 2005 the CHMP agreed on a list of outstanding issues 
to be addressed in writing by the applicant . 
The applicant submitted the responses to the CHMP list of outstanding issues on 02 June 2005. 
During the meeting on  20-23 June 2005, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Xyrem  on  23  June  2005.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 23 June 2005. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 13 October 2005. 
 
